Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Essex Bio-Technology ( (HK:1061) ) has provided an announcement.
Essex Bio-Technology Limited has announced the completion of the last patient last visit in an international multi-centre phase 3 clinical study for HLX04-O, a bio-pharmaceutical product for treating wet-AMD. This study compares the efficacy and safety of HLX04-O with ranibizumab, aiming to fill a gap in the Chinese market where no bevacizumab product for wet-AMD is currently approved.
More about Essex Bio-Technology
Essex Bio-Technology Limited is a biopharmaceutical company focused on developing innovative treatments, particularly in the field of ophthalmology. The company co-develops bio-pharmaceutical products such as anti-VEGF drugs for treating conditions like exudative (wet) age-related macular degeneration, collaborating with partners like Shanghai Henlius Biotech, Inc.
YTD Price Performance: -2.72%
Average Trading Volume: 270,616
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.62B
For an in-depth examination of 1061 stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- 3 Penny Stocks to Watch Now, 1/7/25
- Super Micro Computer Stock Jumps 15% on Liquid Cooling Tech Prospects
- Meta Appoints Trump Ally Dana White to Board
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
